StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
October 25, 2018 7:30 AM
RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $200.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Sarepta Therapeutics (SRPT) PT Lowered to $168 at Piper Jaffray on 3Q Report; Lower Projected Enterprise Value Due to 'Eventual Cannibalization by DMD GeneRx'
October 25, 2018 7:54 AM
Sarepta Therapeutics (SRPT) Posts Smaller-than-Expected Q3 Loss
October 24, 2018 4:10 PM
Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments
October 24, 2018 4:06 PM
